Childhood cancer survivorship: An update on evolving paradigms for understanding pathogenesis and screening for therapy-related late effects

Current Opinion in Pediatrics

Volumn 25, Issue 1, 2013, Pages 16-22

  Armenian, Saro H ^a   Robison, Leslie L ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

childhood cancer; genetics; late effects; medical interventions; survivorship

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BLEOMYCIN; CORTICOSTEROID; METHOTREXATE; PLATINUM DERIVATIVE;

AVASCULAR NECROSIS; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CATARACT; CHILDHOOD CANCER; CHILDHOOD MORTALITY; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; CORTICOSTEROID INDUCED OSTEOPOROSIS; ENDOCRINE DISEASE; HEARING IMPAIRMENT; HIGH RISK PATIENT; HUMAN; HYPOGONADISM; LOW DRUG DOSE; LUNG FIBROSIS; NEUROLOGICAL COMPLICATION; OSTEOPENIA; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; REVIEW; SECOND CANCER; SHORT STATURE;

ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; COGNITION DISORDERS; ENDOCRINE SYSTEM DISEASES; HUMANS; LONG-TERM CARE; MASS SCREENING; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; SURVIVORS;

EID: 84873823991     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32835b0b6a     Document Type: Review

References (52)

1. Ries L, Eisner M, Kosary C, et al. Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD; 2008. http://seer.cancer.gov/csr/1975- 2005/. [Accessed 31 August 2012
2. Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER website April 2012. [Accessed 31 August 2012
3. Mariotto AB, Rowland JH, Yabroff KR, et al. Long-Term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev 2009; 18:1033-1040
4. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355:1572-1582
5. Robison LL, Armstrong GT, Boice JD, et al. The Childhood Cancer Survivor Study: A National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 2009; 27:2308-2318
6. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22:4979-4990
7. Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. Nat Rev Cancer 2002; 2:124-132
8. Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study. J Natl Cancer Inst 2010; 102:1083-1095
9. de Vathaire F, Hawkins M, Campbell S, et al. Second malignant neoplasms after a first cancer in childhood: Temporal pattern of risk according to type of treatment. Br J Cancer 1999; 79:1884-1893
10. Olsen JH, Moller T, Anderson H, et al. Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries. J Natl Cancer Inst 2009; 101:806-813
11. Reulen RC, Frobisher C, Winter DL, et al. Long-Term risks of subsequent primary neoplasms among survivors of childhood cancer. JAMA 2011; 305: 2311-2319
12. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst 2001; 93:618-629
13. Armstrong GT, Plana JC, Zhang N, et al. Screening adult survivors of childhood cancer for cardiomyopathy: Comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012; 30:2876-2884
14. Hawkins MM, Lancashire ER, Winter DL, et al. The British Childhood Cancer Survivor Study: Objectives, methods, population structure, response rates and initial descriptive information. Pediatr Blood Cancer 2008; 50:1018-1025
15. Armstrong GT, Liu W, Leisenring W, et al.Occurrence of multiple subsequent neoplasms in long-Term survivors of childhood cancer: A report from the childhood cancer survivor study. J Clin Oncol 2011; 29:3056-3064
16. Nottage K, McFarlane J, Krasin MJ, et al. Secondary colorectal carcinoma after childhood cancer. J Clin Oncol 2012; 30:2552-2558
17. Henderson TO, Oeffinger KC, Whitton J, et al. Secondary gastrointestinal cancer in childhood cancer survivors: A cohort study. Ann Intern Med 2012; 156:757-766
18. Best T, Li D, Skol AD, et al. Variants at 6q21 implicate PRDM1 in the etiology of therapy-Induced second malignancies after Hodgkin lymphoma. Nat Med 2012; 17:941-943
19. Veiga LH, Bhatti P, Ronckers CM, et al. Chemotherapy and thyroid cancer risk: A report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 2011; 21:92-101
20. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008; 94:525-533
21. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009; 339:b4606
22. van Dalen EC, van der Pal HJ, Kok WE, et al. Clinical heart failure in a cohort of children treated with anthracyclines: A long-Term follow-up study. Eur J Cancer 2006; 42:3191-3198
23. van der Pal HJ, van Dalen EC, van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 2012; 30:1429-1437
24. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-Term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342:1077-1084
25. Armenian SH, Sun CL, Shannon T, et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood 2011; 118:6023-6029
26. Blanco JG, Sun CL, Landier W, et al. Anthracycline-Related Cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase genes: A report from the Children's Oncology Group. J Clin Oncol 2012; 30:1415-1421
27. Visscher H, Ross CJ, Rassekh SR, et al. Pharmacogenomic prediction of anthracycline-Induced cardiotoxicity in children. J Clin Oncol 2012; 30: 1422-1428
28. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23:2629-2636
29. Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- And radiationassociated cardiomyopathies: Implications for screening and prevention. Pediatr Blood Cancer 2005; 44:600-606
30. Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: Report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008; 121:e387-e396
31. Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: Is our ear really to the ground? J Clin Oncol 2008; 26:1201-1203
32. Hundley WG, Bluemke DA, Finn JP, et al. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 2010; 55:2614-2662
33. Armstrong GT, Plana JC, Zhang N, et al. Screening adult survivors of childhood cancer for cardiomyopathy: Comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012; 30:2876-2884
34. Fallah-Rad N, Walker JR, Wassef A, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011; 57:2263-2270
35. Chemaitilly W, Sklar CA. Endocrine complications in long-Term survivors of childhood cancers. Endocr Relat Cancer 2010; 17:R141-R159
36. Patterson BC, Wasilewski-Masker K, Ryerson AB, et al. Endocrine health problems detected in 519 patients evaluated in a pediatric cancer survivor program. J Clin Endocrinol Metab 2012; 97:810-818
37. Meacham LR, Chow EJ, Ness KK, et al. Cardiovascular risk factors in adult survivors of pediatric cancer-A report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 2010; 19:170-181
38. Oudin C, Simeoni MC, Sirvent N, et al. Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. Blood 2011; 117:4442-4448
39. Gurney JG, Ness KK, Sibley SD, et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer 2006; 107:1303-1312
40. Steinberger J, Sinaiko AR, Kelly AS, et al. Cardiovascular risk and insulin resistance in childhood cancer survivors. J Pediatr 2011; 160: 494-499
41. Baxter-Jones AD, Faulkner RA, Forwood MR, et al. Bone mineral accrual from 8 to 30 years of age: An estimation of peak bone mass. J Bone Miner Res 2011; 26:1729-1739
42. Wilson CL, Dilley K, Ness KK, et al. Fractures among long-Term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer 2012. [Epub ahead of print]
43. Kaste SC, Jones-Wallace D, Rose SR, et al. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: Frequency of occurrence and risk factors for their development. Leukemia 2001; 15:728-734
44. Polgreen LE, Petryk A, Dietz AC, et al. Modifiable risk factors associated with bone deficits in childhood cancer survivors. BMC Pediatr 2012; 12:40
45. Reimers TS, Ehrenfels S, Mortensen EL, et al. Cognitive deficits in longterm survivors of childhood brain tumors: Identification of predictive factors. Med Pediatr Oncol 2003; 40:26-34
46. Campbell LK, Scaduto M, Sharp W, et al A meta-Analysis of the neurocognitive sequelae of treatment for childhood acute lymphocytic leukemia. Pediatr Blood Cancer 2007; 49:65-73
47. Mulhern RK, Kepner JL, Thomas PR, et al. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-Dose craniospinal irradiation: A Pediatric Oncology Group study. J Clin Oncol 1998; 16:1723-1728
48. Ris MD, Packer R, Goldwein J, et al. Intellectual outcome after reduceddose radiation therapy plus adjuvant chemotherapy for medulloblastoma: A Children's Cancer Group study. J Clin Oncol 2001; 19:3470-3476
49. Kadan-Lottick NS, Brouwers P, Breiger D, et al. Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 2009; 27:5986-5992
50. Kadan-Lottick NS, Brouwers P, Breiger D, et al A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. Blood 2009; 114:1746-1752
51. Kirchhoff AC, Krull KR, Ness KK, et al. Physical, mental, and neurocognitive status and employment outcomes in the childhood cancer survivor study cohort. Cancer Epidemiol Biomarkers Prev 2011; 20:1838-1849
52. Krull KR, Annett RD, Pan Z, et al. Neurocognitive functioning and health-related behaviours in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Eur J Cancer 2011; 47:1380-1388